secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K/A
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001104659-24-078585
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent appoints Kristine Peterson to Board; she joins Compensation Committee
------------------------------------------------------------------------------

- Kristine Peterson appointed as Class III director effective April 20, 2024, until 2027 annual meeting.
- Appointed to Compensation Committee on July 3, 2024.
- Received option grant with $352,500 fair value, vesting over three years; annual cash retainer of $45,000 prorated.
- Peterson brings >30 years biopharma experience; former CEO of Valeritas, exec roles at J&J and BMS.
- Currently on boards of Immunocore and Enanta; deemed independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924078585/0001104659-24-078585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924078585/tm2419108-1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer